APPENDIX A:

PubMed search history, conducted in April 2019

"Carcinoma, Non-Small-Cell Lung/surgery"[Mesh] OR "Carcinoma, Non-Small-Cell Lung/radiotherapy"[Mesh] OR (("Carcinoma, Non- Small-Cell Lung"[Mesh] OR "Non-Small-Cell Lung Carcinoma"[Title/abstract] OR "Non-Small-Cell Lung Carcinomas"[Title/abstract] OR "Non-Small-Cell Lung cancer"[Title/abstract] OR "Non-Small-Cell Lung cancers"[Title/abstract] OR NSCLC[title/abstract]) AND (Surgery[Title/abstract] OR surgeries[Title/abstract] OR surgical[Title/abstract] OR operation[Title/abstract] OR operations[Title/abstract] OR operative[Title/abstract] OR Radiotherapy[Title/abstract] OR Radiotherapies[Title/abstract] OR "Radiation Therapy"[Title/abstract] OR "Radiation Therapies"[Title/abstract] OR "Radiation Treatment"[Title/abstract] OR "Radiation Treatments"[Title/abstract] OR radiochemotherapy[title/abstract] OR radiosurgery[title/abstract])) AND ((stage[title/abstract] AND III[title/abstract]) OR "stage IIIa"[title/abstract] OR "stage IIIb"[title/abstract] OR "stage IIIc"[title/abstract] OR advanced[title/abstract]) AND (random*[title/abstract] OR "Controlled "[ptyp] OR "Randomized Controlled Trial"[ptyp] OR "Clinical Trial, Phase III"[ptyp]) AND ("1987/01/01"[PDAT] : "3000/12/31"[PDAT])

APPENDIX B: Included studies and their respective treatment arms

Table 1: Overview of the included studies Public Reporting N = Treatment regimen per study arm Phase 2 Random- Funding Geo- Toxicity Mean ation system or 3 isation grap as end- follow- studies hy point up [mo] Burkes et al 1992 ECOG 42 ChT+S+ChT - - - p2 - unknown NA x RChT+S+RC Strauss et al 1992 Not specified 45 hT - - - p2 R* publ NA x 53 Crinò et al 1993 Not specified 61 RChT RT - - n/a R* unknown EU - Kubota et al 1994 Not specified 63 ChT+RT ChT - - n/a R* publ Asia - Pujol et al 1994 WHO criteria 33 ChT+S+RT ChT+RT - - p2 R* publ EU x 16 Rosell et al 1994 Not specified 60 ChT+S S - - n/a R* priv EU x Roth et al 1994 CTCAE v.1 60 ChT+S S - - n/a R* unknown NA - Wagner et al 1994 Not specified 57 ChT+S RT+S - - p2 R* publ NA x Darwish et al 1995 WHO criteria 46 ChT+S+/-RT - - - p2 R* unknown EU - glob Jeremic et al 1996 RTOG 131 RT RChT - - n/a R* unknown al - CTCAE unknown v + Tannehill et al 1997 RTOG/EORTC 26 RChT1 RChT2 - - p2 R* publ NA x Bonner JA 1998 CTCAE v.1 99 RT RT RChT - p3 R* publ NA - Isokangas et al 1998 WHO criteria 27 ChT+RChT - - - n/a - priv EU x 19 glob Jeremic et al 1998 RTOG/EORTC 47 RChT - - - p2 R* unknown al - Furuse et al 1999 WHO/EORTC 314 RChT RT+ RChT - - p3 R* publ Asia x 60 Ichinose et al 1999 JCOG criteria 17 RChT - - - n/a - unknown Asia - 24 Felip et al 2000 WHO criteria 83 ChT1+S ChT2+S - - n/a R* unknown EU x 19 Segawa et al 2000 WHO criteria 50 RChT - - - p2 R* unknown Asia x 41 Takamori et al 2000 WHO criteria 22 RChT+S - - - n/a - unknown Asia x Ulutin et al 2000 RTOG 45 RT RChT1 RChT2 - n/a - unknown Asia - 16 glob Jeremic et al 2001 RTOG/EORTC 195 RChT1 RChT2 - - p2 R* publ al x Elias et al 2002 Not specified 50 RT+S+RT ChT+S+ChT - - n/a R* unknown NA - CTCAE Johnstone et al 2002 unknown v 73 ChT+S+ChT CHt+RT+ChT ChT - p3 R* unknown NA x 48 Kim et al 2002 WHO criteria 89 RChT RT - - p3 R* priv Asia - Pergolizzi et al 2002 WHO criteria 40 RT - - - p2 R* unknown EU x Cappuzzo et al 2003 CTCAE v.2 129 RChT - - - n/a R* unknown EU x CTCAE unknown v + Leong et al 2003 RTOG 60 ChT1+RChT ChT2+RChT - - n/a R* priv Asia x 14 Nagai et al 2003 JCOG criteria 62 ChT+S S - - p3 R* publ Asia - 74.4 CTCAE Schild et al 2003 unknown v 234 RChT1 RChT2 - - p3 R* publ NA - 43 WHO criteria + Ulutin et al 2003 RTOG/EORTC 51 RChT RT - - n/a R* unknown Asia - 14 Cakir et al 2004 WHO criteria 176 RT RChT - - p3 R* unknown Asia - QLQ Schumacher et Symptome ChT+RChT+ al 2004 scale 54 S ChT+S+RT - - p3 R* unknown EU - ChT1(+S)+R Sculier et al 2004 WHO criteria 351 T ChT2(+S)+RT - - p3 R* unknown EU x 47.7 ChT+RChT+ Semik et al 2004 Not specified 273 S ChT+S+RT - - p3 R* publ EU x Zatloukal et al 2004 WHO criteria 102 concRChT seqRChT - - n/a R* publ EU x 39 Atagi et al 2005 CTCAE v.2 46 RT RChT - - p3 R* publ Asia x CTCAE unknown v + RChT+ Belani et al 2005 RTOG 256 ChT1+RChT ChT2+RChT ChT - p2 R* priv NA x 39.6 Belani et al 2005 CTCAE v.2 119 ChT+RT1 ChT+RT2 - - p3 R* publ NA x Beslija et al 2005 WHO criteria 60 ChT+RT RT - - p2 R* unknown EU - Choy et al 2005 CTCAE 51 ChT+RT+Me - - - p2 - priv NA x 36.7 unknown v di Van Schil et al 2005 CTCAE v.3 308 IndCht+RT IndChT+S - - n/a R* priv EU x 70 Gouda et al 2006 RTOG 60 ChT+RChT RChT RT - n/a R* unknown EU x Misirlioglu et al 2006 Not specified 66 RT +Vitamin RT - - n/a R* unknown Asia - ChT+RT Scagliotti et al 2006 CTCAE v.2 89 ChT+RChT - - n/a R* priv EU - Yokomise et al 2006 RTOG 41 RChT1+S RChT2+S - - n/a R* unknown Asia - Esteban et al 2007 WHO criteria 154 ChT1+S/RT ChT2+S/RT - - n/a R* unknown EU x 36 Hamouda et al 2007 WHO criteria 66 ChT+ RT RT - - n/a R* unknown EU x 15 Patel et al 2007 RTOG/EORTC 35 ChT+RChT - - - p2 - priv NA - 45 Perry et al 2007 Not specified 37 (S)+ChT (S)ChT+RT - - p3 R* publ NA - Tawfik et al 2007 CTCAE v.2 27 ChT+RChT - - - p2 - unknown EU x Vokes et al 2007 Not specified 331 RChT ChT+RChT - - n/a R* priv NA x 38 Yang et al 2007 RTOG 55 ChT+RT1 ChT+RT2 - - n/a R* unknown Asia x Hanna et al 2008 CTCAE v.3 147 RChT+ChT RChT - - p3 R* priv NA x 41.6 CTCAE v.3 + Hughes et al 2008 RTOG 12 ChT+RT/IT - - - n/a - publ EU x 10 RChT+ChT1 Kelly et al 2008 CTCAE v.2 543 +ChT2 RChT+ChT1 - - p3 R* priv NA - 27 CTCAE v.3 + ChT+ Nyman et al 2008 RTOG 151 ChT+RChT1 ChT+RChT2 RChT3 - n/a R* priv EU x 52 Socinski et al 2008 CTCAE v.2 68 ChT1+RChT ChT2+RChT - - p2 R* publ NA - 44 Stinchcombe et al 2008 CTCAE v.2 23 ChT+RChT - - - n/a - priv NA x 30 CTCAE Stupp et al 2008 unknown v 46 RchT+S - - - p2 - priv EU x 58 Berghmans et al 2009 CTCAE v.2 49 RChT+CT CT+RChT - - p3 R* priv EU - 51 Garrido et al 2009 CTCAE v.2 139 RChT+ChT ChT+RChT - - p2 R* priv EU - 57 Harada et al 2009 CTCAE v.3 59 RChT1 RChT2 - - n/a - unknown Asia - 30 Friedel et al 2010 Not specified 120 RchT+S - - - p2 - unknown Asia - Girard et al 2010 CTCAE v.3 + 46 ChT+S RChT1+S RChT2+ - p2 R* priv EU x 31.4 Lent Soma S (Fra) (late) Hallqvist et al 2010 CTCAE v.3 75 ChT+RChT - - - p3 - priv EU x 39 Lu et al 2010 CTCAE v.2 379 ChT+RChT ChT+RChT - - p3 R* publ NA x 44.4 glob Movsas et al 2010 CTCAE v.2 64 RChT+ChT1 RChT+ChT2 - - p2 R* priv al - 41.5 Nawrocki et al 2010 CTCAE v.2 99 RT RChT - - p2 R* priv EU x 41 CTCAE v.2 + Pöttgen et al 2010 RTOG/EORTC 28 RChT - - - n/a R* publ EU - 42 Segawa et al 2010 CTCAE v.2 200 RChT1 RChT2 - - p3 R* unknown Asia - glob Senan et al 2010 CTCAE v.3 70 ChT+RChT RChT+ChT - - p2 R* priv al x 14.3 Sun et al 2010 WHO criteria 60 ChT+S ChT+TCM+S - - n/a R* unknown Asia - Takeda et al 2010 JCOG criteria 68 ChT+RChT - - - p2 - publ Asia - Xu et al 2010 CTCAE v.3 21 RChT - - - p2 - unknown Asia x 15 Govindan et al 2011 CTCAE v.3 101 RChT1 RChT - - p2 R* publ NA - 32 2012/ CTCAE v.2 + Atagi et al 2018 RTOG/EORTC 200 RChT RT - - p3 R* publ Asia x 19.4 ChT+RT+Ch Carter et al 2012 CTCAE v.2 119 T ChT+RT - - p3 R* priv NA - 36 ChT+RT+Ch Hoang et al 2012 CTCAE v.2 119 T ChT+RT - - p3 R* priv NA - 36 Katakami et al 2012 CTCAE v.2 58 IndChT+S RChT+S - - p3 R* publ Asia x 60.7 Wang et al 2012 CTCAE v.2 65 RChT1 RChT2 - - p2 R* publ Asia - 46 CTCAE v.3 + Chen et al 2013 RTOG 99 ChT+RT1 ChT+RT2 - - n/a R* unknown Asia - 33.6 CTCAE v.3 + Choy et al 2013 RTOG (late) 98 RChT1 RChT2 - - n/a R* priv NA x ChT+RChT Eberhardt et al 2013 Not specified 64 +/- S - - - p2 R* priv EU x 107 CTCAE v.3 + Kaira et al 2013 RTOG 41 RChT+/-ChT - - - p2 - unknown Asia x 15.1 Oh et al 2013 CTCAE v.3 93 RChT1 RChT2 RChT3 - p3 R* publ Asia x Sugawara et al 2013 CTCAE v.3 70 RChT1 RChT2 - - p2 R* unknown Asia x RChT + Aggarwal et al 2014 Not specified 249 RChT RChT + S S - n/a - unknown NA - Akopov et al 2014 Not specified 42 ChT+S PDT+ChT+S - - n/a R* unknown Asia - Arrieta et al 2014 CTCAE v.3 35 RChT+NO - - - n/a - unknown NA x 18.9 Debus et al 2014 Not specified 385 RChT RChT+Epo - - p3 R* priv EU - Maguire et al 2014 CTCAE v.3 130 RChT ChT+RT - - p2 R* publ EU x 35.2 Shen et al 2014 CTCAE v.3 140 S+RChT S+ChT - - n/a R* unknown Asia x van den Heuvel et al 2014 CTCAE v.3 102 RChT RChT+IT - - p2 R* priv EU - 29 Ahn et al 2015 CTCAE v.3 420 RChT RChT+ChT - - p3 R* priv Asia x 50.7 RChT1+ RChT+ Cetuxi- Cetuxi- Bradley et al 2015 CTCAE v.3 544 RChT1 RChT2 mab mab p2 R* priv NA - 21.2 Crvenkova et al 2015 RTOG/EORTC 85 RChT1 RChT2 - - n/a R* unknown EU - Eberhardt et al 2015 CTCAE v.3 161 RChT+Boost RChT+S - - p3 R* priv EU - 78 CTCAE v.2 + RTOG + Lent Fournel et al 2015 Soma 127 ChT+RChT RChT+ChT - - p2 R* priv EU x 17.7 Pless et al 2015 CTCAE v.1 232 ChT+RT+S ChT+S - - n/a R* priv EU x MWA+R- Xu et al 2015 Not specified 98 (Ch)T R-(Ch)T - - n/a R* unknown Asia x 24 Yao et al 2015 CTCAE v.3 40 RChT RChT+S1 - - n/a R* publ Asia - WHO criterai + Zhu et al 2015 RTOG/EORTC 63 RChT+Tx RChT - - n/a R* unknown Asia x WHO criteria + glob Ardizzoni et al 2016 EORTC/RTOG 151 ChT+RT ChT+RChT - - p3 R* priv al x 73.2 Feng et al 2016 CTCAE v.3 72 RChT+S1 RChT - - n/a R* unknown Asia x Kong et al 2016 CTCAE v.4 49 RT +/- ChT1 RT +/-ChT2 - - n/a - publ Asia x 21.4 Lin et al 2016 CTCAE v.3 130 ChT1+RChT ChT2+RChT - - p3 R* publ Asia x glob Senan et al 2016 CTCAE v.3 598 RChT1 RChT2 - - p3 R* priv al - 22.4 Sun et al 2016 CTCAE v.3 19 RChT+/-ChT - - - p2 - publ Asia x Zhao et al 2016 Not specified 60 RChT+TCM RChT - - n/a R* unknown Asia - Zhao et al 2016 CTCAE v.3 100 RChT1 RChT2 - - p3 R* priv Asia x 2017/ glob Antonia et al 2018 CTCAE v.4 709 RChT+IT RChT - - p3 R* priv al x Edelman et al 2017 CTCAE v.4 71 RChT+/- S RChT+IT +/- S - - p2 R* priv NA - Liang et al 2017 CTCAE v.3 191 RChT1 RChT2 - - p3 R* publ Asia x 73 Ramella et al 2017 CTCAE v.4 50 RChT - - - n/a - unknown EU x 25.8 Crvenkova et al 2018 RTOG/EORTC 95 RChT1 RChT2 - - n/a R* publ EU - Hallqvist et al 2018 CTCAE v.4 36 RChT1 RChT2 - - p2 R* publ EU x 49 Sasaki et al 2018 CTCAE v.3 108 RChT1 RChT2 - - p2 R* priv Asia x 31.9 Sculier et al 2018 WHO criteria 120 RChT1 RchT2 - - p3 R* unknown EU x 62 Xiong et al 2019 CTCAE v.3 19 ChT+S - - - p2 - priv Asia x R = radiotherapy, S = surgery, ChT = , RChT = radiochemotherapy, Numbers = regimen Nr 1, regiment nr 2 (e.g. RChT1 differs in dose or chemo- agents from RChT2), EPO = erythropoietin, p2 = phase II study, p3 = phase 3 study, n/a = not applicable, R* = randomised, priv = privately sponsored, publ = publicly sponsored, EU = European study, NA = North American study, Asia = asian study

APPENDIX C: overview of all the 231 reported AEs

Acute AE # of studies reporting 119 Acne 4 Allergic reaction 8 Alopecia 29 Anaemia 74 Anorexia 22 ARDS/Resp failure 7 Arrhytmia 6 Aspiration 4 Asthenia 5 Athralgia 6 Bilirubin ↑ 5 Bleeding/Hemorrhage 15 Bowel fistula 4 Bronchitis 4 bronchopleural fistula 5 Cardiorespiratory arrest 5 Cerebral infarction 7 Chest pain 4 Chills 4 Constipation 16 Cough 15 Crea ↑ 24 Decreased Appetite 7 Dehydration 11 Depression 4 Dermatitis 9 Diarrhea 38 Dizziness 5 Dry skin 4 duodenal ulcer 4 Dysgeusia 4 Dyspepsia 5 Dysphagea 15 Dyspnoea 26 Edema 7 Eruption 4 Esophageal fistula 4 Esophageal Perforation 5 Esophagitis 77 Failure to thrive 4 Fatigue 38 Febrile neutropenia 41 Fever 20 Fluid Retention 4 Flushing 5 Gastric ulcer 4 Gastritis 4 GI Pain 4 GI-Hemmorrhage 4 Haematemesis 4 Haematotoxicity 14 Headache 7 Hearloss 9 Hemoptysis 9 Herpes Gastritis 4 Hiccups 4 Hyperbilirubinemia 4 Hypercalcemia 4 Hyperglycemia 5 Hypersensitivity 8 Hypertension 4 Hyperthyreoidism 4 Hypoalbuminaemia 4 Hypocalcemia 5 Hypokalemia 9 Hypomagnesiemia 5 Hyponatremia 9 Hypotension 11 Hypothyreoidism 4 Hypovolemic shock 4 Hypoxia 7 Ileus 4 Infection 39 Injection Site reaction 6 Leukopenia 62 Liver Enzymes ↑ 21 Lung fistula 5 Lymphopenia 9 Mediastinitis 4 Mucositis 8 Muscular weakness 4 Myalgia 5 Myelosuppression 4 Myocardial infarction 8 Nausea 77 Neuropathy/PNP 27 Neutropenia 71 OAW infection 4 Orthostatic hypotension 4 Ototoxicity 6 Pain 12 Pancreatitis 5 Pericardial effusion 4 Pneumonia 17 Pneumothorax 4 Pruritus 5 PTT elevated 4 Pulmonary Edema 5 Radiation Pneumonitis 66 Radiation recall reaction 4 Rash 15 Sepsis 9 Skin Reaction 6 Sleep disturbance 4 Sneezing 4 Somnolence 4 Sore mouth 4 Stomatitis 15 Syncope 5 Taste alteration 4 Thrombocytopenia 75 Thrombosis/Embolus 14 Tremor 4 unknown cause of dath 4 Ventricular Arrhythmia 4 Vomiting 66 Weakness 4 Weightloss 14 Wheeze/Stridor 4

Late AE 23 Anemia 4 anterior spinal cord syndrome 4 Cough 5 Dysphagia 4 Dyspnoea 5 Esophageal perforation 5 Esophageal stenosis 11 Esophagitis 4 Fatigue 4 Hearing 4 Lung fibrosis 9 Lymphopenia 3 Motor deficit 4 Mucosisitis 4 Neuropathy 6 Pain 4 Pancytopenia 4 Pneumonitis 9 Pulmonary Hemorrhage 4 Renal failure 5 RT injury 4 second malignancy 4 Weightloss 4

Organ acute 19 Blood/BM 8 Bone/osseous 4 Cardiac 16 Constitutional sympt. 4 Esophagus 13 GI 15 Hemoglobin 4 Hemorrhage/Bleeding 4 Infection 4 Mental 4 Metabolic/Lab 5 Neruological 9 Neurology 6 Other 5 other 4 Renal 14 Respiratory 27 Skin 11 Urinary 6

Organ late 10

Blood/BM 4 Bone/Osseous 5 Cardiac 6 Constitutional sympt. 4 Esophagus 13 GI 5 Neurological 4 Renal 4 Respiratory 14 Skin 5 Surgical 58 Air leak 4 ARDS 8 Arrhythmia 8 Aspiration 4 Atelectasis 6 Brochopulm Hemorrhage 6 Bronchial obstruction/Fistula 13 Bronchitis 5 broncho-esophageal fistula 4 Cardiac arrest 5 Cardiac decompensation 4 Cardiac disorders 4 cardiac failure 4 cardiac herniation 4 Chylothorax 5 COPD Exacerbation 4 Cough 4 CVI 6 Dyspnoe 5 Emphysema 5 Empyema 9 Fever 3 Haematoma 4 Haemothorax 4 heart lucation 4 Hemoptysis 4 Hemorrhage 7 Ileus 6 Infection 8 Injury, poisoning and procedural complications 4 Metabolism nutritional disorder 4 Myocardial ischemia 7 Nerve lesion 4 other cases of death 5 Other complications 8 perioperatice toxicity 5 Pneumopathy 5 Pneumothorax 4 Pneuomnia 10 Pneuomonitis 5 Prolonged ventilation 5 Pulmonary embolism 6 Pulmonary hypertension 3 radial nerve palsy 4 Re-OP 7 Respiratory Failure 9 Secrete retention 4 Seroma 4 Space problems 4 Stump insufficiency 7 Suture dehiscence 5 Thromboembolic diseas 8 Toxic death 4 uncontrolled diabetes 4 UTI 4 vocal cord paralysis 5 Wound hematoma 4 wound Infection 4

Surgical late 2 Cvi 4 Pneumonia 5

APPENDIX D: References of the included studies

1. Xiong, L., et al., Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2). Oncologist, 2019. 24(2): p. 157-e64. 2. Crvenkova, S., Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated With Combination of Chemotherapy and Conformal Radiotherapy. Open Access Maced J Med Sci, 2018. 6(12): p. 2323-2327. 3. Sasaki, T., et al., A randomised phase II trial of S-1 plus versus plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer, 2018. 119(6): p. 675-682. 4. Atagi, S., et al., Thoracic radiotherapy with or without daily low-dose in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol, 2012. 13(7): p. 671-8. 5. Hallqvist, A., et al., Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. Lung Cancer, 2018. 122: p. 180-186. 6. Sculier, J.P., et al., A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer, 2018. 117: p. 32-37. 7. Antonia, S.J., et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 2018. 379(24): p. 2342-2350. 8. Antonia, S.J., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. N Engl J Med, 2019. 380(10): p. 990. 9. Edelman, M.J., et al., Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. J Thorac Oncol, 2017. 12(9): p. 1413-1420. 10. Ramella, S., et al., Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC. J Thorac Oncol, 2017. 12(7): p. 1122-1130. 11. Liang, J., et al., and cisplatin versus and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol, 2017. 28(4): p. 777-783. 12. Lin, H., et al., Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. Front Oncol, 2016. 6: p. 260. 13. Kong, M. and S.E. Hong, Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage III non-small cell lung cancer. Onco Targets Ther, 2016. 9: p. 7227-7234. 14. Ardizzoni, A., et al., Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent -based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016. 100: p. 30-37. 15. Feng, J., et al., S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial. Medicine (Baltimore), 2016. 95(36): p. e4557. 16. Senan, S., et al., PROCLAIM: Randomized Phase III Trial of -Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 2016. 34(9): p. 953-62. 17. Zhao, Q., et al., Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer. Oncotarget, 2016. 7(7): p. 8422-31. 18. Eberhardt, W.E., et al., Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol, 2015. 33(35): p. 4194-201. 19. Pless, M., et al., Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, 2015. 386(9998): p. 1049-56. 20. Xu, X., et al., Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study. Med Oncol, 2015. 32(9): p. 227. 21. Ahn, J.S., et al., Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol, 2015. 33(24): p. 2660-6. 22. Crvenkova, S. and M. Pesevska, Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy. J BUON, 2015. 20(3): p. 775-81. 23. Bradley, J.D., et al., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by- two factorial phase 3 study. Lancet Oncol, 2015. 16(2): p. 187-99. 24. Yao, L., et al., S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial. Radiat Oncol, 2015. 10: p. 10. 25. Akopov, A., et al., Preoperative endobronchial improves resectability in initially irresectable (inoperable) locally advanced non small cell lung cancer. Photodiagnosis Photodyn Ther, 2014. 11(3): p. 259-64. 26. Arrieta, O., et al., Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer. Radiother Oncol, 2014. 111(2): p. 311-5. 27. Aggarwal, C., et al., Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control, 2014. 21(1): p. 57-62. 28. van den Heuvel, M.M., et al., Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol, 2014. 110(1): p. 126-31. 29. Choy, H., et al., Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol, 2013. 8(10): p. 1308-16. 30. Eberhardt, W.E.E., et al., 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)— A multicenter phase-II trial (CISTAXOL). Lung Cancer, 2013. 82(1): p. 83-89. 31. Chen, M., et al., Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study. Biomed Res Int, 2013. 2013: p. 371819. 32. Katakami, N., et al., A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer, 2012. 118(24): p. 6126-35. 33. Carter, D.L., et al., A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer, 2012. 13(3): p. 205-13. 34. Sun, X.F., et al., Application of Aidi injection (艾迪注射液) in the bronchial artery infused neo-adjuvant chemotherapy for stage III A non-small cell lung cancer before surgical operation. Chin J Integr Med, 2010. 16(6): p. 537-41. 35. Girard, N., et al., Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer, 2010. 69(1): p. 86-93. 36. Pöttgen, C., et al., Intensified High-Dose Chemoradiotherapy With Induction Chemotherapy in Patients With Locally Advanced Non– Small-Cell Lung Cancer—Safety and Toxicity Results Within a Prospective Trial. International Journal of Radiation Oncology*Biology*Physics, 2010. 76(3): p. 809-815. 37. Berghmans, T., et al., A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer, 2009. 64(2): p. 187-93. 38. Hanna, N., et al., Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol, 2008. 26(35): p. 5755-60. 39. Hughes, S., et al., A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol, 2008. 3(6): p. 648-51. 40. Yang, K., et al., Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT. Front Med China, 2007. 1(4): p. 381-5. 41. Hamouda, W., et al., Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer. Gulf J Oncolog, 2007(2): p. 55-64. 42. Vokes, E.E., et al., Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 2007. 25(13): p. 1698-704. 43. Perry, M.C., et al., A Phase III Study of Surgical Resection and Paclitaxel/Carboplatin Chemotherapy with or Without Adjuvant Radiation Therapy for Resected Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B 9734. Clinical Lung Cancer, 2007. 8(4): p. 268-272. 44. Choy, H., et al., Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 2005. 23(25): p. 5918-28. 45. Van Schil, P., et al., Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J, 2005. 26(2): p. 192-7. 46. Semik, M., et al., Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer. Eur J Cardiothorac Surg, 2004. 26(6): p. 1205-1210. 47. Zatloukal, P., et al., Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer, 2004. 46(1): p. 87-98. 48. Schumacher, A., et al., Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer, 2004. 44(1): p. 89-97. 49. Sculier, J.P., et al., A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol, 2004. 15(3): p. 399-409. 50. Cakir, S. and I. Egehan, A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer, 2004. 43(3): p. 309-16. 51. Schild, S.E., et al., The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol, 2003. 21(17): p. 3201-6. 52. Cappuzzo, F., et al., and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. Cancer, 2003. 98(1): p. 128-34. 53. Leong, S.S., et al., Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol, 2003. 21(9): p. 1767-74. 54. Nagai, K., et al., A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg, 2003. 125(2): p. 254-60. 55. Cüneyt Ulutin, H. and Y. Pak, Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer. J Cancer Res Clin Oncol, 2003. 129(1): p. 52-6. 56. Johnstone, D.W., et al., Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 2002. 54(2): p. 365-9. 57. Elias, A.D., et al., Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clin Lung Cancer, 2002. 4(2): p. 95-103. 58. Pergolizzi, S., et al., Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions. Is curative irradiation feasible? Final results of a prospective study. Lung Cancer, 2002. 37(2): p. 201-6. 59. Kim, T.Y., et al., A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small- cell lung cancer. Am J Clin Oncol, 2002. 25(3): p. 238-43. 60. Takamori, S., et al., A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer. Lung Cancer, 2000. 29(1): p. 49-56. 61. Jeremic, B., et al., Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys, 2001. 50(1): p. 19-25. 62. Felip, E., et al., Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial. Clin Lung Cancer, 2000. 1(4): p. 287-93. 63. Ulutin, H.C., et al., Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. Radiat Med, 2000. 18(2): p. 93-6. 64. Segawa, Y., et al., A phase II study of cisplatin and 5- with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer, 2000. 82(1): p. 104-11. 65. Furuse, K., et al., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, , and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol, 1999. 17(9): p. 2692-9. 66. Ichinose, Y., et al., UFT plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Oncology (Williston Park), 1999. 13(7 Suppl 3): p. 98-101. 67. Jeremic, B., et al., Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. Int J Radiat Oncol Biol Phys, 1998. 42(5): p. 1091-6. 68. Isokangas, O.P., et al., Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC. Lung Cancer, 1998. 20(2): p. 127-33. 69. Bonner, J.A., et al., The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer, 1998. 82(6): p. 1037-48. 70. Tannehill, S.P., et al., Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol, 1997. 15(8): p. 2850-7. 71. Jeremic, B., et al., Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol, 1996. 14(4): p. 1065-70. 72. Darwish, S., et al., A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Lung Cancer, 1995. 12 Suppl 1: p. S71-8. 73. Wagner, H., et al., Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, , and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881. Chest, 1994. 106(6 Suppl): p. 348S-354S. 74. Pujol, J.L., et al., Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer. Chest, 1994. 106(5): p. 1451-5. 75. Kubota, K., et al., Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol, 1994. 12(8): p. 1547-52. 76. Roth, J.A., et al., A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non- small-cell lung cancer. 1994(0027-8874 (Print)). 77. Rosell, R., et al., A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small- cell lung cancer. N Engl J Med, 1994. 330(3): p. 153-8. 78. Crinò, L., et al., Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non- small-cell lung cancer. Ann Oncol, 1993. 4(10): p. 847-51. 79. Strauss, G.M., et al., Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. Journal of Clinical Oncology, 1992. 10(8): p. 1237-1244. 80. Burkes, R.L., et al., Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. Journal of Clinical Oncology, 1992. 10(4): p. 580-586. 81. Zhu, X.P., et al., A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res, 2015. 14(3): p. 10228-35. 82. Sun, X.J., et al., A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer. BMC Cancer, 2016. 16: p. 266. 83. Zhao, Z., H. Liao, and Y. Ju, Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy. J Tradit Chin Med, 2016. 36(1): p. 14-8. 84. Fournel, P., et al., Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. Eur J Cancer, 2015. 52: p. 181-7. 85. Maguire, J., et al., SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer, 2014. 50(17): p. 2939-49. 86. Debus, J., et al., Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa. Radiother Oncol, 2014. 112(1): p. 23-9. 87. Oh, I.J., et al., A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401. Cancer Chemother Pharmacol, 2013. 72(6): p. 1247-54. 88. Kaira, K., et al., Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer, 2013. 82(3): p. 449-54. 89. Sugawara, S., et al., Randomized phase II trial of uracil/ and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. Lung Cancer, 2013. 81(1): p. 91-6. 90. Wang, L., et al., Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2012. 77(1): p. 89-96. 91. Hoang, T., et al., Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol, 2012. 30(6): p. 616-22. 92. Govindan, R., et al., Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol, 2011. 29(23): p. 3120-5. 93. Xu, Y., et al., Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lung Cancer, 2010. 72(3): p. 327-32. 94. Senan, S., et al., A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol, 2010. 22(3): p. 553-8. 95. Hallqvist, A., et al., Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group. Lung Cancer, 2010. 71(2): p. 166-72. 96. Takeda, K., et al., A phase II study of cisplatin and as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol, 2010. 41(1): p. 25- 31. 97. Nawrocki, S., et al., Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study. J Thorac Oncol, 2010. 5(8): p. 1255-62. 98. Segawa, Y., et al., Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol, 2010. 28(20): p. 3299-306. 99. Lu, C., et al., Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst, 2010. 102(12): p. 859-65. 100. Movsas, B., et al., Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer. J Thorac Oncol, 2010. 5(5): p. 673-9. 101. Harada, H., et al., Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. Int J Clin Oncol, 2009. 14(6): p. 507-12. 102. Nyman, J., et al., How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer, 2008. 65(1): p. 62-7. 103. Socinski, M.A., et al., Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol, 2008. 26(15): p. 2457-63. 104. Kelly, K., et al., Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 2008. 26(15): p. 2450-6. 105. Stinchcombe, T.E., et al., Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol, 2008. 3(3): p. 250-7. 106. Patel, S.H., et al., A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). J Thorac Oncol, 2007. 2(9): p. 831-7. 107. Tawfik, H.A., A.l.-H. Taha, and G.A. Attia, Induction Docetaxel and Cisplatin Followed by Weekly Docetaxel and Cisplatin with Concurrent Radiotherapy in Locally Advanced Stage III Non Small Cell Lung Cancer (LA-NSCLC)-A Phase II Study. J Egypt Natl Canc Inst, 2007. 19(1): p. 15-20. 108. Esteban, E., et al., Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study. Lung Cancer, 2007. 55(2): p. 173-180. 109. Scagliotti, G.V., et al., Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer, 2006. 94(10): p. 1375-82. 110. Gouda, Y.S., et al., Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Natl Canc Inst, 2006. 18(1): p. 73-81. 111. Misirlioglu, C.H., et al., Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial. Med Oncol, 2006. 23(2): p. 185-9. 112. Belani, C.P., et al., Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol, 2005. 23(25): p. 5883-91. 113. Beslija, S., et al., Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer. J BUON, 2005. 10(3): p. 347-55. 114. Belani, C.P., et al., Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non- small-cell lung cancer. J Clin Oncol, 2005. 23(16): p. 3760-7. 115. Atagi, S., et al., Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol, 2005. 35(4): p. 195-201. 116. Yokomise, H., et al., Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg, 2007. 133(5): p. 1179-85. 117. Shen, W.-y., et al., Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial. Radiotherapy and Oncology, 2014. 110(1): p. 120-125. 118. Friedel, G., et al., Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol, 2010. 28(6): p. 942-8. 119. Stupp, R., et al., Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol, 2009. 10(8): p. 785-93.